AstraZeneca hit the skids today on news that Dresdner Kleinwort has lowered the drug major to 'sell' from 'reduce', although the price target stays at 2,000p.
The German broker called the stock "expensive not defensive" and recommended investors steer clear of the near-term risk regarding patents and thin drug pipeline.
No comments:
Post a Comment